Haemonetics Corporation $HAE is North Peak Capital Management LLC’s 5th Largest Position

North Peak Capital Management LLC lifted its position in Haemonetics Corporation (NYSE:HAE) by 204.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,102,992 shares of the medical instruments supplier’s stock after acquiring an additional 740,626 shares during the quarter. Haemonetics accounts for 7.5% of North Peak Capital Management LLC’s portfolio, making the stock its 5th largest position. North Peak Capital Management LLC owned about 2.37% of Haemonetics worth $88,405,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. True Wealth Design LLC lifted its holdings in shares of Haemonetics by 6,700.0% in the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 335 shares during the last quarter. Leonteq Securities AG bought a new stake in shares of Haemonetics in the 4th quarter worth about $30,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 396 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Haemonetics in the 4th quarter worth about $34,000. Finally, Bayforest Capital Ltd bought a new stake in shares of Haemonetics in the 4th quarter worth about $40,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Down 2.4%

NYSE:HAE opened at $77.89 on Friday. Haemonetics Corporation has a one year low of $47.31 and a one year high of $87.32. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.87 and a current ratio of 2.95. The firm has a market cap of $3.54 billion, a P/E ratio of 38.56, a P/E/G ratio of 1.57 and a beta of 0.56. The firm has a 50-day simple moving average of $62.27 and a 200-day simple moving average of $67.36.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business had revenue of $346.35 million during the quarter, compared to analyst estimates of $336.83 million. During the same quarter in the previous year, the business posted $1.24 EPS. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Equities analysts anticipate that Haemonetics Corporation will post 5.23 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on HAE. Citigroup raised their target price on shares of Haemonetics from $64.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday, May 28th. Bank of America upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $72.00 to $80.00 in a report on Friday, May 22nd. Mizuho decreased their price objective on shares of Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Monday, April 13th. JPMorgan Chase & Co. decreased their price objective on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Finally, Weiss Ratings lowered shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Haemonetics presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.11.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.